Name assigned to new cancer drug
Ariad is developing the new entity in conjunction with Merck for the treatment of solid tumors and hematologic cancers.
Ariad Pharmaceuticals has announced the official nonproprietary name for its mTOR inhibitor, AP23573. The new name, as approved by the United States Adopted Names (USAN) Council is deforolimus. Ariad is developing the new entity in conjunction with Merck for the treatment of solid tumors and hematologic cancers. The drug has been granted both fast-track and orphan drug status by the FDA and, according to Ariad, will enter a phase III trial this quarter in patients with metastatic sarcoma.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
